Aparito and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) revolutionised ataxia studies by configuring the Aparito Atom5™ mobile app to monitor Ataxia symptoms at home using a validated SARAhome assessment. This collaboration utilises the innovative video capture and analysis functionality of the Atom5™ platform.

The collaboration is about the development and further assessment of a new app displaying the SARAhome scale within Aparito’s flagship software platform Atom5™. This way SARAhome is made available to patients on iOS and Android and is currently available in English, German, Dutch and Portuguese. Throughout the cooperation, it will be rolled out in multiple study sites in Europe, including the DZNE in Bonn, and Melbourne Australia over the coming months. 

A main benefit of the SARAhome app is that it enables close monitoring of Ataxia symptoms within a significantly brief period of time: Ataxia symptoms can be highly variable within a single day, from day to day and week to week. Travel to clinical sites can be stressful and time-consuming for patients, also impacting on a patient’s performance while being assessed and often leading to missed insight into disease variability. 

A recent publication by Dr Marcus Grobe-Einsler et al (2020) in the Journal Movement Disorders demonstrated the validity and feasibility of SARAhome. First data from the home application suggests that fluctuations in the severity of ataxia exceed the expected range.